TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00983619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-551
Description: MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Study: NCT02868502

Intervention type: DEVICE
Intervention: Tonopen XL
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus

Intervention type: DEVICE
Intervention: ICare rebound tonometer
Description: IOP measurement in the sitting position and lateral decubitus
Study: NCT01019408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Study: NCT03358862

Intervention type: DEVICE
Intervention: NaturalVue Multifocal Contact Lens
Description: NaturalVue multifocal contact lenses are daily disposable, distance center, multifocals with a novel extended depth of focus optical design. Patients wearing their habitual corrections who opt to change to this new lens will have their myopia progression monitored for up to two years.
Study: NCT02406781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of MK3475 with Metronomic CP
Description: Combination of MK3475 with Metronomic CP. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of MK3475 with Metronomic CP and G100
Description: Combination of MK3475 with Metronomic CP and G100. Metronomic CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.~MK3475 will be administered intravenously (200 mg), and given every 3 weeks on day 8.~G100 will be administered by intra-tumoral injection (20µg), one weekly injection for at least 6 weeks and for a maximum of 12 weeks. G100 will start one week before CP administration (impregnation phase).~A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation.
Study: NCT01500174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultraviolet therapy UV254
Description: three times per week until wound closure or patient discharge from hospital

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultraviolet therapy UV254
Description: Three times per week irradiation of wound base and periwound skin
Study: NCT01499238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal SIMV
Description: rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
Study: NCT02637180

Intervention type: DRUG
Intervention: anti-osteoporotic medication
Description: check previous information
Study: NCT02044939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Description: Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
Study: NCT03567551

Intervention type: OTHER
Intervention: Women w/ Preeclampsia w/o Visual Disturbances or Headache
Description: Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
Study: NCT01455090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-650032
Study: NCT00983619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
Study: NCT02034084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left radial approach
Description: Coronary diagnostic procedures performed through left radial approach

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right radial approach
Description: coronary diagnostic procedures performed through right radial approach
Study: NCT04387890

Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic SARS-CoV-2 screening
Description: Quantitative Indirect Chemiluminescence Immunoassay (CLIA) to access SARS-CoV-2 specific IgM and IgG serum antibody level every 2 weeks during follow up
Study: NCT00691028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650 3 mg/kg
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study: NCT01499238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal CPAP
Description: PEEP: 4-6 mmHg, FİO2: 40%
Study: NCT00691028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650 6 mg/kg
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-650 10 mg/kg
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Study: NCT00890630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracervical Balloon Catheter
Description: Intracervical insertion of an 80cc Double-Balloon Catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
Study: NCT02273310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Skills Training for Disease Management
Description: Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
Study: NCT01001494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 200 μg bid
Description: Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 400 μg bid
Description: Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice-daily by inhalation for 24 weeks
Study: NCT04022369

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The intervention group received 45-60 minute of individual training and a handbook for the exercise program was given. These patients were followed for a total of 12 weeks. The weekly motivational phone calls structured according to the empowerment model and home visits when necessary were repeated. The exercise program was developed by reviewing the literature part on physical activity for senior citizens with heart failure. The program was established on evidence-based recommendations for the cardiac rehabilitation of patients with HF. Each session included warm-up and cool-down exercises, moderate walking, and balance exercises.
Study: NCT01373645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yinyi stent
Description: subjects with Yinyi stent implantation
Study: NCT00738192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl citrate
Description: Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil citrate
Description: Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Butorphanol tartrate
Description: Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
Study: NCT03503851

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip implantation
Description: Device to approximate the mitral valve leaflets

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip implantation
Description: Device to approximate the mitral valve leaflets
Study: NCT01083927

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotational Narrow Strip Conjunctival Graft
Description: Surgical technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full Conjunctival Graft
Description: Surgical technique
Study: NCT04389970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants will eat all food within an 8 hour window each day. They will only consume water or black coffee during the remaining 16 hours.
Study: NCT04993222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposome for injection
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposome for injection
Description: IV infusion
Study: NCT03567551

Intervention type: OTHER
Intervention: Women w/ Preeclampsia w/ Visual Disturbances or Headaches
Description: Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant

Intervention type: OTHER
Intervention: Women w/o Preeclampsia
Description: Up to three maternal blood samples collected from each participant, cerebrospinal fluid collected from each participant during spinal or combined spinal/epidural anesthesia, one umbilical cord blood sample obtained from each participant, four placenta samples obtained from each placenta from each participant
Study: NCT02717260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial random noise stimulation (tRNS) (Starstim)
Description: subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial random noise stimulation (tRNS) (Starstim)
Description: subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial random noise stimulation (tRNS) (Starstim)
Description: subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
Study: NCT01102907

Intervention type: OTHER
Intervention: Liquid Breakfast
Description: The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk

Intervention type: OTHER
Intervention: Solid Breakfast Meal
Description: The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
Study: NCT04993222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome®
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AmBisome®
Description: IV infusion
Study: NCT03350984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPH insulin
Description: NPH insulin twice daily, 2/3 in the morning and 1/3 in the night. A correctional dose of lispro insulin will be given for any blood glucose \>180 mg/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine and Lispro insulin
Description: Half of the total Glargine and Lispro insulin dose will be given as glargine once daily, either in the morning or in the evening, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as Lispro; doses were divided equally between breakfast, lunch, and dinner.
Study: NCT01341951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor
Description: 300 I.U twice daily for 5 days
Study: NCT03332082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth positioner
Description: Orthodontic Tooth positioners treatment have been used in the Orthodontic Industry for many years. These positioners are used for small minor movements to complete the final smile. These positioners are made from a biocompatible and FDA approved clear silicone material after the teeth have been set to the final position.
Study: NCT01203254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Colesevelam 625 mg tablet; 3 times daily 2 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet: 3 times daily 2 tablets
Study: NCT04459767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: 80 mg subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vupanorsen
Description: 80 mg subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT02568982

Intervention type: OTHER
Intervention: Exams and questionnaires
Description: Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
Study: NCT03470974

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-titration strategy
Description: The self-titration strategy allows patients or medical professionals to adjust their medicine (additional, maintain, or decrease dose) depending on a bespoke plan. The bespoke plan for hypertensive patients involves setting target blood pressure, self-monitoring blood pressure, recording blood pressure readings and constructing a medication titration schedule. Each medication titration step is conducted based on the average home BP measurement readings.
Study: NCT02723578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg PO once daily on days 1-21 every 21 days
Study: NCT03574324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPF+CCRT
Description: Patients receive Neoadjuvant Docetaxel (75mg/m2 on day1 03:30-04:30) and cisplatin (75mg/m2 on day 1-5 10:00-22:00) and 5-FU(750mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles followed by concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: CCRT+PF
Description: Patients receive concurrent cisplatin (100mg/m2 on day1 10:00-22:00)every 21 days for three cycles during radiotherapy followed by adjuvant cisplatin (80mg/m2 on day 1-5 10:00-22:00) and 5-FU(800mg/m2 on day 1-5 22:00-10:00) every 21days for three cycles
Study: NCT04173364

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Injectable solution of ropivacaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% Injectable Solution
Description: Dilution of ropivacaine to the concentration of 0.1%
Study: NCT02172170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773 single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03023046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03226873

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Navigation
Description: Peer education, counseling, and facilitation of PrEP care